The Future of OSD?
The technologies and treatments set to revolutionize the way we approach ocular surface disease
Preeya Gupta | | Longer Read
Ocular surface disease (OSD) is more widespread than many clinicians once thought. Recent studies have shown that the majority of patients presenting for cataract surgery have ocular signs of dry eye or Meibomian gland dysfunction (MGD), regardless of whether they report symptoms (1, 2). My colleagues and I have demonstrated that signs of MGD, once thought to be a condition limited to postmenopausal women, are common even in children (3).
Although we are fortunate to have a wide array of treatments for OSD, including artificial lubricants, topical anti-inflammatory drops, thermal pulsation, and punctal occlusion, many patients get insufficient relief from these approaches. There are a number of new and pipeline treatments designed to address the gaps in treatment.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Login
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
